Therefore, combining ICIs with VEGF-A inhibitors, such as bevacizumab, has emerged as an appealing treatment strategy for EGFR mutant NSCLC after driver-targeted therapy failure (60–62). Here, EGFR is linked to non-small cell lung carcinoma.